COMPARISON OF EFFICACY OF TAMSULOSIN, ALFUZOSIN, AND SILODOSIN IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA

APARNA RETNAYYAN; SYAM SREEDHARAN; FREDRICK PAUL RETHINASWAMY; HARISANKAR KARAKKAATTILLAM NARAYAN NAMPOOTHIRI; BRIGHTY MATHEW

doi:10.22159/ajpcr.2023.v16i2.46439

Authors

APARNA RETNAYYAN Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.
SYAM SREEDHARAN Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.
FREDRICK PAUL RETHINASWAMY Department of Urology, Government Medical College, Kottayam, Kerala, India.
HARISANKAR KARAKKAATTILLAM NARAYAN NAMPOOTHIRI Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.
BRIGHTY MATHEW Department of Pharmacology, Government Medical College, Kottayam, Kerala, India. https://orcid.org/0000-0001-9305-227X

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i2.46439

Keywords:

benign prostatic hyperplasia, alpha 1 adrenoceptor blocker, Tamsulosin, Alfuzosin, Silodosin, lowe urinary tract symptoms.

Abstract

Objectives: This study was done to determine the efficacy of alpha-1 adrenoceptor blockers such as tamsulosin, alfuzosin, and silodosin in patients with the lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) over 6 months by assessing change in international prostate symptom score (IPSS), quality of life scale for urinary symptoms (Bother score), and improvement in peak urine flow rate (Qmax) from baseline. We also tried to identify any adverse drug reactions (ADRs) caused by these drugs.

Methods: A prospective observational study was conducted in 291 patients with LUTS secondary to BPH attending urology outpatient department of a tertiary care center for 1 year. Ninety-seven patients in each group received tamsulosin, alfuzosin, or silodosin once daily. IPSS, Qmax, and the quality of life scale for urinary symptoms by Bother score were assessed at 1st, 3rd, and 6th month of treatment period. ADR was noted and recorded in ADR reporting form.

Results: IPSS, mean bother score, and mean Qmax showed significant improvement from the baseline in each follow-up visit at 1, 3, and 6 months for all the three groups, but maximum was for alfuzosin and was found to be statistically significant (p<0.001). Two patients developed adverse drug reaction during the study; asthenia in tamsulosin group and hypotension in Silodosin group.

Conclusion: Patients on alfuzosin showed maximum improvement in the values of IPSS, Bother score, and Qmax in BPH patients as compared to tamsulosin and silodosin. Alfuzosin would be a better choice in the treatment of LUTS due to BPH.

Downloads

Download data is not yet available.

Author Biographies

FREDRICK PAUL RETHINASWAMY, Department of Urology, Government Medical College, Kottayam, Kerala, India.

Department of Urology, Associate Professor

HARISANKAR KARAKKAATTILLAM NARAYAN NAMPOOTHIRI, Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.

Department of Pharmacology, Assistant Professor

References

Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol 2016;48:134-40.

Jayakumar V, Varghese PA, Johnson AT, Karthik V, Babitha M. Assessment of comparative patient satisfaction and side-effects associated with tamsulosin versus silodosin therapy in benign prostate hyperplasia. Asian J Pharm Clin Res 2021;14:35-40.

Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005;7(Suppl 9):S3-1.

Rani V, Venepally S. A cost variation analysis study of drugs used in the management of benign prostatic hyperplasia available in the Indian market. Asian J Pharm Clin Res 2021;14:152-5.

Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol 2014;46:601-7.

Manohar CM, Nagabhushana M, Karthikeyan VS, Sanjay RP, Kamath AJ, Keshavamurthy R. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH: A double blind randomized trial. Cent European J Urol 2017;70:148-53.

De la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256-63; discussion 264.

Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int 2014;113:623-35.

Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: The new paradigm. Can J Urol 2008;15 Suppl 1:21-30; discussion 30.

Bid HK, Konwar R, Singh V. Benign prostatic hyperplasia: Is it a growing public health concern for India? Indian J Med Sci 2008;62:373-4.

Benign Prostatic Hyperplasia (BPH): Practice Essentials, Background, Anatomy. Available from: https://emedicine.medscape.com/ article/437359-overview [Last accessed on 2020 Dec 08].

Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991;337:1457-61.

Roni MA, Kibria G, Jalil R. Formulation and in vitro evaluation of alfuzosin extended release tablets using directly compressible Eudragit. Indian J Pharm Sci 2009;71:252-8.